Purpose The aim of this study was to report the clinical outcome of the three-piece AcrySof MA60AC intraocular lens (IOL) in opacified IOL exchange surgery. Patients and methods This is a retrospective multicenter study that included 53 eyes of 53 patients with visually disabling IOL opacification requiring surgery. The medical records of the patients were reviewed for comorbidities, previous cataract surgery, and other ocular procedures. The details of IOL exchange surgery were reported. The primary outcome measures were best corrected visual acuity at the sixth postoperative month and postoperative complications, while the secondary outcome measures were comorbidities, time between IOL implantation and its opacification, and intraoperative complications. Results The most common comorbidity was diabetes mellitus (64.2%). The mean interval between IOL implantation and opacification was 4.36±2.9 years. The intraoperative complications included zonular dehiscence (11.3%) and posterior capsule rupture (7.5%). In 67.9% of the cases, the IOL was implanted in the bag and in 32.1% in the ciliary sulcus, with 7.5% of the latter requiring scleral fixation. There was a statistically significant improvement in best corrected visual acuity from 1.07 ±0.19 Log MAR preoperatively to 0.29±0.49 Log MAR postoperatively (P<0.001). Minimal postoperative complications were recorded that included transient increased intraocular pressure in 5.7% and cystoid macular edema in 7.5% of the cases. No IOLs showed opacification or decentration. No serious complications were reported throughout the study period. Conclusions The AcrySof MA60AC IOL was a safe and effective IOL for the patients requiring IOL replacement due to visually impairing IOL opacification. The diversity of implantation of this IOL whether in the bag or in the ciliary sulcus, with or without scleral fixation is advantageous in cases of IOL exchange in which insufficient capsular support is frequently encountered.